Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy

Blank, Simon; Etzold, Stefanie; Darsow, Ulf; Schiener, Maximilian; Eberlein, Bernadette; Russkamp, Dennis; Wolf, Sara; Graessel, Anke; Biedermann, Tilo; Ollert, Markus; Schmidt-Weber, Carsten B

Published in:
Human Vaccines & Immunotherapeutics

DOI:
10.1080/21645515.2017.1323603

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY-NC-ND

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy

Simon Blank, Stefanie Etzold, Ulf Darsow, Maximilian Schiener, Bernadette Eberlein, Dennis Russkamp, Sara Wolf, Anke Graessel, Tilo Biedermann, Markus Ollert & Carsten B. Schmidt-Weber

To cite this article: Simon Blank, Stefanie Etzold, Ulf Darsow, Maximilian Schiener, Bernadette Eberlein, Dennis Russkamp, Sara Wolf, Anke Graessel, Tilo Biedermann, Markus Ollert & Carsten B. Schmidt-Weber (2017) Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy, Human Vaccines & Immunotherapeutics, 13:10, 2482-2489, DOI: 10.1080/21645515.2017.1323603

To link to this article: http://dx.doi.org/10.1080/21645515.2017.1323603

© 2017 The Author(s). Published with license by Taylor & Francis® Simon Blank, Stefanie Etzold, Ulf Darsow, Maximilian Schiener, Bernadette Eberlein, Dennis Russkamp, Sara Wolf, Anke Graessel, Tilo Biedermann, Markus Ollert, and Carsten B. Schmidt-Weber

Accepted author version posted online: 11 May 2017.
Published online: 11 May 2017.

Article views: 527

View Crossmark data

View related articles

Citing articles: 3 View citing articles
Component-resolved evaluation of the content of major allergens in therapeutic extracts for specific immunotherapy of honeybee venom allergy

Simon Blanka,†, Stefanie Etzolda, Ulf Darsowb, Maximilian Schienera, Bernadette Eberleinb, Dennis Russkampa, Sara Wolfa, Anke Graessela, Tilo Biedermannb, Markus Ollertc,d,e, and Carsten B. Schmidt-Weberc

aCenter of Allergy and Environment (ZAUM), Technical University of Munich and Helmholtz Center Munich, Member of the German Center of Lung Research (DZL), Munich, Germany; bDepartment of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany; cInstitute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany; dDepartment of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg; eDepartment of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, University of Southern Denmark, Odense C, Denmark

ABSTRACT
Allergen-specific immunotherapy is the only curative treatment of honeybee venom (HBV) allergy, which is able to protect against further anaphylactic sting reactions. Recent analyses on a molecular level have demonstrated that HBV represents a complex allergen source that contains more relevant major allergens than formerly anticipated. Moreover, allergic patients show very diverse sensitization profiles with the different allergens. HBV-specific immunotherapy is conducted with HBV extracts which are derived from pure venom. The allergen content of these therapeutic extracts might differ due to natural variations of the source material or different down-stream processing strategies of the manufacturers. Since variations of the allergen content of therapeutic HBV extracts might be associated with therapeutic failure, we addressed the component-resolved allergen composition of different therapeutic grade HBV extracts which are approved for immunotherapy in numerous countries. The extracts were analyzed for their content of the major allergens Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10. Using allergen-specific antibodies we were able to demonstrate the underrepresentation of relevant major allergens such as Api m 3, Api m 5 and Api m 10 in particular therapeutic extracts. Taken together, standardization of therapeutic extracts by determination of the total allergenic potency might imply the intrinsic pitfall of losing information about particular major allergens. Moreover, the variable allergen composition of different therapeutic HBV extracts might have an impact on therapy outcome and the clinical management of HBV-allergic patients with specific IgE to particular allergens.

CONTACT Dr. Simon Blank simon.blank@tum.de Center of Allergy and Environment (ZAUM), Institute of Allergy Research Helmholtz Center Munich Ingolstädter Landstraße 1, D-85764 Munich, Germany; Prof. Dr. Markus Ollert markus.ollert@lih.lu Department of Infection and Immunity Luxembourg Institute of Health (LIH) 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg.

Research in this field has been supported by the German Research Foundation (DFG), the European Community’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 262074 (EuroAsthma), the Excellence Initiative of the German federal and state governments, the Luxembourg Development Cooperation, and the Foundation for Allergy Research.

†These authors contributed equally to this work.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

ARTICLE HISTORY Received 16 March 2017 Revised 10 April 2017 Accepted 24 April 2017

KEYWORDS allergen content; allergen-specific antibody; allergen-specific immunotherapy; Api m 3; Api m 5; Api m 10; honeybee venom allergy; hymenoptera venom; venom extract; venom immunotherapy

Introduction
Stings of Hymenoptera such as honeybees or wasps can cause severe and even fatal anaphylaxis in allergic individuals. The only curative treatment which is effective in reducing the risk of subsequent systemic reactions is venom-specific immunotherapy (VIT). VIT is effective in 75% to 98% of patients in preventing sting anaphylaxis. However, therapy failures occur more often in honeybee venom (HBV) compared with yellow jacket venom (YJV) allergy.

HBV represents a complex mixture of various substances such as low-molecular weight components (e.g. histamine, noradrenalin, serotonin and dopamine), peptides (e.g., melittin, apamin, kinins and mast cell degranulating peptide) and a plethora of proteins from which several are allergens. VIT is performed with venom extracts which are administered either as aqueous or aluminum hydroxide-adsorbed extracts (depot preparations). The latter are used in the conventional build-up and maintenance phases, while the aqueous extracts are used in ultra-rush, rush, clustered and maintenance phases. Interestingly, in Europe many specialists switch from aqueous extracts to depot preparations after up-dosing.

All therapeutic HBV extracts are derived from pure venom, which is usually collected by electrostimulation, a procedure which leads to a relatively pure venom. Another possibility for obtaining venom extract is the dissection of whole venom glands which is usually collected by electrostimulation, a procedure which leads to a relatively pure venom. Another possibility for obtaining venom extract is the dissection of whole venom glands and venom sacs, a method yielding less pure extract since in addition to the venom components, also proteins from the surrounding tissue are contained in the extract. However, only scarce information is available about how the venom is further processed by different manufacturers to produce therapeutic...
grade venom extracts. Although this classification is a little misleading in the literature, aqueous venom extracts are sometimes classified as "purified" and "non-purified" extracts.\(^7\)\(^8\) This terminology results from the fact that, even though, all manufacturers surely undertake purification steps of the pure venom for injection purposes, some companies claim to offer an ultrapure venom extract for therapy which does not contain vasoactive amines and a reduced content of small peptides.\(^4\) In the commonly used licensed depot preparation, the "purified" extract is adsorbed onto aluminum hydroxide. In comparative trials, the purified aqueous and the purified aluminum hydroxide-adsorbed extracts appear to be better tolerated than non-purified extracts, especially in terms of severe local reactions.\(^7\)\(^8\)

Although the production of therapeutic allergen extracts has to be highly standardized in terms of the production process and of the total allergenic potency,\(^9\) the lack of information about a broader range of clinically relevant allergens and of appropriate molecular tools for their assessment hampers the generation of highly reliable venom extracts with a more favorable overall therapeutic efficacy.

Especially HBV might represent a challenge for the preparation of therapeutic extracts including all relevant allergens in adequate amounts, since over 60% of its dry-weight is made up by the allergens Api m 1 (12%) and Api m 4 (50%).\(^10\) While Api m 1 (phospholipase A2) represents a well-established major allergen, Api m 4 (melittin) is a minor allergen with restricted clinical relevance.\(^5\) Recently it was demonstrated that HBV contains many more additional important major allergens, namely Api m 2 (hyaluronidase), Api m 3 (acid phosphatase), Api m 5 (dipeptidyl peptidase IV) and Api m 10 (scarapin) which exhibit IgE reactivity with 47.9–52.2%, 49.6–50%, 58.3–61.7% and 61.8–72.2% of allergic patient’s sera, respectively.\(^11\)\(^12\) Compared to Api m 1 and Api m 4, all these allergens are present in the venom in only minimal amounts.\(^13\)\(^14\) This might implicate that especially the amount of these allergens in therapeutic extracts, might be easily affected by natural variations of the source material, different work-up strategies of the manufacturers or even by degradation of particular components.

In a former study we used monoclonal antibodies and demonstrated that, compared with crude HBV, the allergens Api m 3 and Api m 10 are underrepresented or even missing in particular therapeutic HBV extracts which are commonly used for VIT.\(^13\) Very recently, another study correlated treatment failures of HBV VIT with a predominant Api m 10 sensitization and demonstrated the lack or underrepresentation of Api m 10 in different therapeutic HBV extracts.\(^14\)

Such data might be of major importance for the clinical management of HBV-allergic patients with specific IgE to particular allergens. Therefore, in this study we extended former analyses and generated highly specific and sensitive antibodies for the detection of the major allergens Api m 2, Api m 3, Api m 5 and Api m 10 and compared different therapeutic HBV extracts regarding their allergen content. Thereby, we were able to demonstrate the underrepresentation of relevant major allergens in particular therapeutic extracts. Moreover, compared with another study,\(^11\) we found dramatically different results concerning the Api m 3 and Api m 10 content of particular products, a fact that is of major importance for clinical decisions on the selection of licensed immunotherapeutic products in Europe. Additionally, our findings on Api m 10 stability might have an impact on the immunotherapeutic procedure for venom allergy, both in Europe and in the United States.

### Results

#### Generation of allergen-specific antibodies

Polyclonal antibodies with specificity for the major allergens Api m 2, Api m 3 and Api m 10 were generated by the immunization of rabbits with the individual purified and cross-reactive carbohydrate determinat (CCD-) free recombinant allergens.\(^12\)\(^13\)\(^15\)\(^16\) For the detection of Api m 5 we used a recombinant monoclonal IgE antibody.\(^17\)

All rabbit antisera that resulted from the immunizations with the individual allergens as well as the monoclonal Api m 5-specific antibody showed excellent reactivity with the

![Figure 1](image-url)

**Figure 1.** Specificity and sensitivity of allergen-specific antibodies. A, Reactivity of the antibodies with their corresponding recombinant target allergens in ELISA. B, Reactivity of the antibodies with their native target allergens in crude honeybee venom. In comparison, the IgE-reactivity of a poolserum from honeybee venom-allergic patients is shown. Since all investigated allergens represent glycoproteins, the molecular weights do not correspond to that of the calculated weights of the protein portions only, which are stated in some databases. C, Detection of the particular allergens in serial dilutions of crude honeybee venom to assess the sensitivity of the allergen-specific antibodies in immunoblot.
recombinant allergens (Fig. 1A). Moreover, all antibodies proved to be highly specific for the natural allergens in the crude HBV and detected single allergen bands of the expected molecular weight in immunoblots (Fig. 1B). The sensitivity of the detection was assessed using dilution series of the crude venom and all antibodies showed adequate detection of their target allergens within 4 μg of whole venom (Fig. 1C).

Allergen content of therapeutic HBV extracts

We addressed the major allergen content of 4 different aqueous therapeutic HBV extracts which are approved for immunotherapy in different countries worldwide: Venomil (Allergy Therapeutics, Worthing, UK), Reless (outside Germany also known as Pharmalgen; ALK-Abelló, Hamburg, Germany), ALK lyophilisiert SQ (outside Germany also known as Aquagen SQ; ALK-Abelló) and Venomenhal (HAL Allergy, Leiden, Netherlands). Furthermore, the allergen content of these therapeutic HBV extracts was compared with 2 commercially available crude HBV extracts (I: Sigma-Aldrich, Taufkirchen, Germany; II: Latoxan, Portes-lès-Valence, France).

For the analyses, all lyophilized extracts were reconstituted with ddH₂O and the freshly reconstituted extracts were applied for immunoblotting. Staining of the major allergen Api m 1 served as loading control to ensure that all extracts were present on the immunoblot at equal amounts (representative stainings are shown in Fig. 2). Api m 1 was present in all therapeutic extracts as well as in the crude venoms in equal and high amounts. Additionally, Api m 2 was well detectable in all therapeutic extracts (Fig. 2A). Api m 3, Api m 5 and Api m 10 were detectable in comparable amounts in Venomil, Reless (Pharmalgen) and Venomenhal, although, to a slightly lesser extent than in the crude HBV (Fig. 2A). However, all 3 allergens were strongly underrepresented and only barely detectable in ALK lyophilisiert SQ (Aquagen SQ) (Fig. 2A).

Intriguingly, while these results were reproducible for 5 batches of Venomil, 2 batches of Reless and 2 batches of ALK lyophilisiert SQ, in another batch of Venomenhal, Api m 3 and Api m 10 were not detectable. The direct comparison of the 3 batches of this product showed that both allergens were well detectable in 2 batches but undetectable in a third batch (Fig. 2B), while the content of the other investigated allergens was comparable for all batches (data not shown).

In a recent study a comparable Api m 3-specific antiserum was used and a clear reactivity of all therapeutic HBV extracts, comparable to that of crude HBV, was postulated. Due to these divergent results we repeated the analysis using an already published monoclonal Api m 3-specific antibody.13 Thereby, we were able to completely confirm our previous results using the polyclonal antiserum, namely, a lesser Api m 3 content of all therapeutic extracts compared with the crude venom and an underrepresentation of Api m 3 in ALK lyophilisiert SQ (Aquagen SQ) compared with the other products (Fig. S1).

Stability of Api m 10

To address the variable Api m 10 content of different therapeutic products and the observed discrepant results for particular products compared with the recently published study by Frick et al.,11 we evaluated the stability of this relevant allergen. Interestingly, applying recombinantly produced and purified Api m 10 in a comparable concentration as found in the crude venom, our analyses demonstrated rapid degradation of the allergen within 3 days, when stored in solution at +4°C (Fig. 3A).

In our analyses we always used freshly reconstituted therapeutic venom extracts. However, the observed instability of Api m 10 could critically influence immunoblot-based analyses in the laboratory. For laboratory purposes the freeze-dried therapeutic venom extracts are routinely solved in ddH₂O or buffers like PBS and not in the supplied albumin-containing saline.

Figure 2. Allergen content of therapeutic honeybee venom extracts. A, Allergen content of therapeutic extracts compared with crude venom as assessed by the use of polyclonal (Api m 2, Api m 3 and Api m 10) and monoclonal (Api m 5) antibodies. Representative results of 5 batches of Venomil (Allergy Therapeutics, Worthing, UK), 2 batches Reless (Pharmalgen) (ALK-Abelló, Hamburg, Germany), 2 batches ALK lyophilisiert SQ (Aquagen SQ) (ALK-Abelló) and 2 batches of Venomenhal (HAL Allergy, Leiden, Netherlands) are shown. Ponceau S staining of Api m 1 served as loading control (a representative staining is shown). B, Api m 3 and Api m 10 content of 3 independent batches (B1-B3) of Venomenhal.
diluent for injection purposes. This implies that some PBS-reconstituted products such as Reless (Pharmalgen) or Venom-ehal contain human serum albumin (HSA) since it is already contained in the freeze-dried venom. In contrast, for Venomil the HSA is added together with the diluent in clinical practice, so that ddH2O- or buffer-reconstituted Venomil contains no HSA. The stabilizing effect of HSA on Api m 10 in crude venom, stored in solution at +4°C, is shown in Fig. 3B. Moreover, these results indicate that laboratory analyses of therapeut-ic venom extracts might be influenced by the reagents used for their reconstitution and by the subsequent storage of the solubi-lized extracts, as demonstrated by the different results for ddH2O-reconstituted Venomil and Reless stored at either -20°C or +4°C (Fig. 3C). However, in clinical practice this fact does not matter since all analyzed products contain HSA after reconstitution with the supplied diluent.

Discussion

In this study we established tools that allow a component-resolved analysis of therapeutic HBV extracts. Four therapeutic HBV extracts commonly used for VIT were analyzed for their content of the major allergens Api m 1, Api m 2, Api m 3, Api m 5 and Api m 10. Intriguingly, numerous differences could be demonstrated for the particular products. The observed varying major allergen content of therapeutic HBV extracts might have a high impact on clinical practice and on the handling of patients with particular sensitization profiles.

Although obtained by methods, yielding relatively pure venom, the analyzed therapeutic HBV extracts showed a diverse content of important major allergens. This degree of variation, as also demonstrated for other allergen extracts, indicates that different strategies for down-stream processing of the pure venom for the production of therapeutic grade venom extracts, can substantially affect the representation of major venom allergens, resulting in the potential loss of particular allergens with high clinical relevance. Moreover, the geographical origin or seasonal variations might additionally affect the composition of the source material.

During the last years, studies demonstrated that in addition to Api m 1 also Api m 2, Api m 3, Api m 5 and Api m 10 repre-sent major allergens of HBV. Additionally, 39 different sensitization profiles were identified in 144 patients with HBV allergy, applying 6 different allergens (Api m 1–5 and 10). Interestingly, in HBV allergy these 6 allergens are necessary to reach a diagnostic sensitivity of approximately 95%, a fact that indicates a more complex allergen composition of HBV compared with YJV. In YJV allergy the 2 major allergens Ves v 1 and 5 are sufficient to reach the same diagnostic sensitiv-ity. Both of the 2 important allergens are present in YJV in substan-tial and equimolar amounts (Ves v 1 with 6–14% and Ves v 5 with 5–10% of the venom dry weight). In contrast, in HBV Api m 1 is the only major allergen that is present in substantial amounts and all other relevant allergens make up only 0.6–2% of the venom dry weight. Therefore, it could be speculated that these differences between the 2 venoms might be a reason for the higher success rate of YJV-specific immunotherapy.

Currently, it is a matter of debate whether particular sen-sitization profiles are linked to the outcome of VIT with HBV. Very recently, a study correlated treatment failures of HBV VIT with a predominant Api m 10 sensitization. The same study demonstrated the lack or underrepresenta-tion of Api m 10 in different therapeutic HBV extracts commonly used for VIT. As a consequence of the variable Api m 10 content, it was suggested that patients with predominate Api m 10 sensitization should be treated with a HBV extract containing a relevant amount of the allergen. To our opinion this is a major step forward toward a personalized medicine approach in VIT and, surely, will influence the use of VIT products. Likewise, it might be an option to treat patients without Api m 10 sensitization with a product that lacks the allergen.

Figure 3. Stability of the major allergen Api m 10. A, Stability of recombinant purified Api m 10 produced in insect cells. Api m 10, in a concentration comparable to that detected in crude venom, was stored for 3 d at +4°C. B, Stability of Api m 10 in crude honeybee venom reconstituted either with HSA-containing diluent for injection (Allergy Therapeutics) or PBS upon storage at +4°C for 4 weeks. C, Detection of Api m 10 in water-resolved Venomil (no HSA in the lyophylisate) and Reless (HSA in the lyophylisate) stored for 4 weeks at either -20°C or +4°C.

A

recombinant Api m 10

day 0 day 1 day 2 day 3

B

crude venom I

+ HSA

- HSA

+ HSA

- HSA

day 0 week 1 week 2 week 3 week 4

C

-20°C +4°C

Venomil® - HSA Reless® + HSA Venomil® - HSA Reless® + HSA Venomil® - HSA Reless® + HSA

Downloaded by [University of Southern Denmark] at 05:15 03 November 2017
In this study, the content of 5 relevant major allergens in 4 aqueous HBV extracts which are commonly used for immunotherapy was addressed for the first time. Thereby, we were able to demonstrate comparable allergen contents for Api m 1 and Api m 2. However, substantial differences were demonstrated for the other allergens. While Api m 3, Api m 5 and Api m 10 could be reproducibly detected in different batches of Venomil and Reless (Pharmalgen), all 3 allergens were clearly underrepresented in ALK lyophilisiert SQ (Aaquagen SQ). An underrepresentation of Api m 3 and Api m 10 was observed for one but not for 2 other batches of Venomenhal. Only one batch of the product was available on the market at a time and the underrepresentation was observed only for the earliest purchased batch. Therefore, the differences in the Api m 3 and Api m 10 content could either be due to batch to batch variations or to a modified production process.

Whether the underrepresentation of the 3 major allergens, which was observed for ALK lyophilisiert SQ (Aaquagen SQ), also holds true for the related depot preparation (ALK-depot SQ or Alutard SQ), can only be speculated at this time point since the analysis of aluminum-adsorbed venom extracts by the here applied methods is very challenging. Recently, the presence of Api m 10-derived peptides was demonstrated for Aaquagen SQ (and Alutard SQ) by mass spectrometry (MS) analyses.27 This is in accordance with our immunoblot analyses which were also able to detect minimal amounts of intact Api m 10 in ALK lyophilisiert SQ (Aaquagen SQ). Nevertheless, our results demonstrate obvious differences in the amount of full-length Api m 10 in this particular product compared with other aqueous extracts. Moreover, while our analyses address the content of the full-length protein, the applied MS analyses are not able to discriminate between full-length Api m 10 and Api m 10-derived degradation products. Additionally, the used MS analyses were not quantitative. However, so far it is not known whether the intact allergen and derived degradation products thereof exhibit the same potency in inducing a tolerogenic immune response. Definitely, further studies are needed, which address, if small amounts of Api m 10 or Api m 10-derived peptides in the therapeutic extracts are sufficient to induce tolerance in the majority of patients. Nevertheless, our analyses suggest that intensive purification and processing steps of the crude venom might strongly influence the content of full-length Api m 10 (as well as of Api m 3 and Api m 5), and since underrepresentation was most pronounced in ALK lyophilisiert SQ (Aaquagen SQ), it’s processing that removes low molecular weight substances and reduces the amount of bioactive peptides, may be relevant here.4,7,8

A recent study demonstrated the lack or underrepresentation of Api m 10 in Venomil, Venomenhal and Aaquagen SQ as well as its presence in Pharmalgen.11 Although in our analyses we applied the same methods, intriguingly, we found dramatically different results in part, a fact that is of major importance for clinical decisions on the selection of licensed immunotherapeutic products in Europe. Our study was able to confirm the underrepresentation of Api m 10 in Aaquagen SQ (ALK lyophilisiert SQ) and its presence in Pharmalgen (Reless). However, in strong contrast to that study, we were able to detect comparable amounts of Api m 10 in 5 independent batches of Venomil. For Venomenhal our analyses demonstrated batch to batch variations ranging from Api m 10 content comparable to Venomil and Pharmalgen to undetectable content. These are facts that might be of importance for the handling of patients with Api m 10 sensitization.

Regarding the reasons for these different results, it can only be speculated. The analyses were reproducibly performed with different independent batches in both studies. The sensitivity of detection is not able to give a reasonable explanation for the observed discrepancy, since the evaluated detection limit of our experimental setup is significantly higher than the postulated detection limit by Frick et al.: Whereas 4–10 μg of crude venom was necessary to achieve adequate detection of Api m 10 in our immunoblots, Frick et al. show effective detection when applying 0.5–1.5 μg of crude venom. Most likely, the observed discrepancies might be explained by the rapid degradation of the allergen after solubilizing the lyophilized therapeutic extracts and storage at + 4° C. Unfortunately, Frick et al. do not state how venom extracts were handled in the laboratory after solubilization. Nevertheless, these data clearly demonstrate the need for standardized operation procedures for quality-control of therapeutic extracts in different laboratories.

In clinical practice in Europe, the observed Api m 10 instability might be limited by the fact that all of the licensed products contain potentially stabilizing human serum albumin after reconstitution of the lyophilized extract. However, our results might implicate that the use of small pharmaceutical phials that contain therapeutic extracts for one injection might be superior over larger ones that are stored for several weeks after reconstitution. However, the obtained results may not only influence clinical decisions for the selection of immunotherapeutic products in Europe. Due to the observed instability of Api m 10, they might also have an impact on the immunotherapeutic procedure in the United States, where the clinical routine practice involves the formulation of patient-specific preparations for immunotherapy based on stock solutions of venom extract stored at + 4° C, exactly the conditions that lead to rapid Api m 10 degradation.

In contrast to a former analysis in which we used an Api m 3-specific monoclonal antibody for detection,13 the study by Frick et al.11 demonstrated the presence of Api m 3 in all assessed therapeutic products in comparable amounts to that in crude HBV by applying polyclonal antibodies. Our analyses shown here, also used polyclonal rabbit antibodies that were generated against full-length Api m 3 produced in insect cells. Surprisingly, these analyses showed clearly lesser amounts of Api m 3 in all therapeutic extracts, compared with crude HBV as well as an underrepresentation in ALK lyophilisiert SQ (Aaquagen SQ) and in 1 out of 3 batches of Venomenhal compared with the other therapeutic extracts. Although, both studies used polyclonal rabbit antibodies, these differences might be explained by slight differences in sensitivity or specificity of detection. In contrast to the antibodies used in our study, which detected a single band of Api m 3, the antibodies used by Frick et al. resulted in multiple bands in some of the analyzed products. Moreover, our results are in full accordance with the data obtained in a former study13 and with the results obtained using the monoclonal Api m 3-specific antibody in this study.

Considering the complex sensitization profiles of HBV-allergic patients,12 it might be speculated that some of the
therapeutic extracts could be associated with therapeutic failure in patients with particular sensitization profiles, an issue that should be addressed in future studies. Potential candidates might be patients who are polysensitized to several allergens or who are exclusively sensitized to allergens such as Api m 3 and/or Api m 10 (4.8% of patients), which are not or only barely detectable in particular therapeutic HBV extracts, and against which, only minimal IgG4 is induced during VIT in contrast to other allergens that are present in substantial amounts. Moreover, the immune response to minimal amounts of allergen in particular HBV extracts might differ strongly in individual patients. Notably, HBV in general might represent a particularly challenging allergen source for the preparation of therapeutic extracts, containing all major allergens in sufficient amounts. Studies of other therapeutic vaccines for allergen immunotherapy demonstrated that maintenance doses of 3 to 20 μg of major allergen are associated with clinical improvement after immunotherapy. Taken a maintenance dose of 100 μg, these amounts are only reached for Api m 1 and none of the other major allergens of HBV, even within crude venom. Therefore, the mechanism of tolerance induction against low amounts of major allergens in the majority of HBV-allergic patients clearly should be a focus of future research. The limitation of our study is represented by the fact that at this time no connection between therapeutic outcome, allergen content of products used for therapy and IgE sensitization profiles of patients can be revealed. Therefore, our results clearly demonstrate the need for extended prospective clinical studies focusing on this relationship.

Nevertheless, our results might have implications for i) the clinical management of HBV-allergic patients particular sensitization profiles worldwide, ii) the quality control and regulatory process for patient-named and licensed products used for VIT procedures, and iii) all major stakeholders (doctors, patients, regulators, reimbursement systems/insurance companies) in the affected health markets, helping them to make the right decisions in the emerging era of precision medicine.

Taken together, our data demonstrate obvious differences in the quality of therapeutic HBV extracts in terms of the content of important allergens, a fact that might be of major importance at least for patients with particular sensitization profiles. Moreover, standardization of therapeutic venom extracts by determination of the total allergenic potency might imply the intrinsic pitfall of losing information about particular major allergens. Allergen-specific antibodies represent valuable tools that allow component-resolved analyses of therapeutic extracts on a molecular level that cope with the advanced knowledge of the composition of relevant allergens.

Materials and methods

Allergen-specific antibodies and recombinant allergens

The recombinant CCD-free allergens were produced in *Spodoptera frugiperda* (Sf9) insect cells and purified as described previously. Polyclonal antibodies were generated by immunization of rabbits (Davids Biotechnology, Regensburg, Germany) with either recombinant Api m 2, Api m 3 or Api m 10 according to established protocols. The monoclonal Api m 3- and Api m 5-specific IgE antibodies were generated as described previously. For immunoblotting, lyophilized HBV extracts were dissolved in ddH2O to a stock concentration of 1.3 mg/mL. Immediately after dissolving 23 μg/lane (or less for sensitivity testing of the antibodies) were separated by SDS-PAGE under reducing conditions and immobilized onto nitrocellulose membranes (Thermo Scientific, 88018). Blot membranes were blocked with 40 mg/mL nonfat dry milk powder (ApplicChem, A0830) in PBS (Life Technologies, 70011051). Polyclonal allergen-specific rabbit antisera were diluted 1:1000 with 20 mg/mL nonfat dry milk powder in PBS. Recombinant monoclonal IgE antibodies were used in form of cell culture supernatants (DMEM (Gibco, 31966–021) supplemented with 10% fetal calf serum (Biochrom, SO115)) of antibody-producing HEK293 cells. All antibodies were applied to the corresponding Western blots and incubated over night at 4 °C. After washing for 3 times with PBS, bound allergen-specific antibodies were detected for 1 hour at room temperature via polyclonal goat anti-rabbit IgG (Sigma-Aldrich, SAB3700854) or monoclonal mouse anti-human IgE (BD Biosciences, 558589) antibody, conjugated to alkaline phosphatase, diluted 1:5000 or 1:1000 with 20 mg/mL nonfat dry milk powder in PBS, respectively. After washing for 3 times with PBS bound antibodies were visualized using nitroblue tetrazolium blue chloride (ApplicChem, A1243)/5-bromo-4-chloro-3-indoyl phosphate (ApplicChem, A1117) according to the recommendations of the manufacturer. Ponceau S (Sigma-Aldrich, P7170) staining of immobilized Api m 1 served as loading control.

Elisa

F96 maxisorp Nunc-immuno plates (Thermo Scientific, 439454) were coated with recombinant allergens (10 μg/mL) overnight at 4 °C and blocked with 10 mg/mL BSA (ApplicChem, A1391) in PBS (Life Technologies, 70011051). Allergen-specific polyclonal rabbit antisera were diluted 1:5000 and monoclonal recombinant antibody cell culture supernatants 1:2 with 5 mg/mL BSA in PBS, applied to the corresponding wells and incubated for 4 hours at room temperature. After washing 5 times with 0.05% Tween20 (EMD Chemicals, 655204) in PBS, alkaline phosphatase-conjugated polyclonal goat anti-rabbit IgG (Sigma-Aldrich, SAB3700854) diluted 1:5000 or monoclonal mouse anti-human IgE (BD Biosciences, 558589) diluted 1:1000 in 5 mg/mL BSA were added for 1 hour at room temperature. After washing 5 times with 0.05% Tween20 in PBS, detection was performed with 5 mg/mL 4-nitrophenylphosphat disodium salt hexahydrate (ApplicChem, A1442) in AP-detection buffer (100 mM Tris, 10 mM MgCl2·6 H2O, 100 mM NaCl, pH 9.5) and signals were read at 405 nm.

Abbreviations

CCD cross-reactive carbohydrate determinant
HBV honeybee venom
HSA human serum albumin
PBS  phosphate-buffered saline
VIT  venom immunotherapy
YJV  yellow jacket venom

Disclosure of potential conflicts of interest

SB has received speaker’s honorarium and/or travel support from ALK-Abellô, Bencard and Thermo Fisher Scientific; has received consultancy fees as an advisory board member and research support from Bencard. UD has been speaker, investigator and/or a member of advisory boards for Allergopharma, ALK-Abellô, Bencard, GSK, Hermla, MEDA, Novartis Pharma, Staller, Steifl. MS has received travel support from ALK-Abellô. TB has received research funding, speaker’s honorarium and consultancy fees from Thermo Fisher Scientific, has received research support from DFG, Novartis and Thermo Fisher Scientific; has received lecture fees from MSD, Novartis, HIP and C19; has received grants from Allergopharma, Leti, PLS-Design and Bencard; has received lecture fees as an advisory board member and research support from Bencard. UD has received honorarium and consultancy fees from Stallergenes, Stiefl. MO has received consultancy fees from Siemens Healthcare; is board member of the Norwegian Research Council. MO has received consultancy fees from Siemens Healthcare; is co-founder of PLS-Design GmbH. The authors declare that they have no conflict of interest.

References


[24] Sturm GJ, Hemmer W, Hawranek T, Lang R, Ollert M, Spillner E, Blank S, Bokanovic D, Aberer W. Detection of IgE to recombinant Api m 1 and Ves v 5 is valuable but not sufficient to distinguish bee


[27] Christensen L, Larsen J, Monsalve R. Identification of allergens in honeybee venom and confirmation of Api m 10 in immunotherapy products as determined by LC-MS/MS. Allergy, asthma, and clinical immunology: official journal of the Canadian Society of Allergy and Clinical Immunology 2016; 71:71
